These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15758701)

  • 21. Effectiveness of tolterodine in nonneurogenic voiding dysfunction.
    Babu R
    Indian Pediatr; 2006 Nov; 43(11):980-3. PubMed ID: 17151401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
    Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
    Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Commentary on tolterodine for men with benign prostatic hyperplasia and lower urinary tract symptoms.
    O'Leary MP
    J Urol; 2008 May; 179(5 Suppl):S86. PubMed ID: 18405764
    [No Abstract]   [Full Text] [Related]  

  • 24. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RE: Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
    Ellsworth P
    J Urol; 2003 Sep; 170(3):928; author reply 928. PubMed ID: 12913741
    [No Abstract]   [Full Text] [Related]  

  • 26. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed incontinence.
    Wein AJ
    J Urol; 2005 Jun; 173(6):2055-7. PubMed ID: 15879826
    [No Abstract]   [Full Text] [Related]  

  • 28. [Therapy of mixed urinary incontinence].
    Goepel M
    Urologe A; 2003 Jun; 42(6):812-7. PubMed ID: 12851773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticholinergic drugs for overactive bladder.
    Kripke C
    Am Fam Physician; 2006 Jan; 73(1):66. PubMed ID: 16417066
    [No Abstract]   [Full Text] [Related]  

  • 30. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solifenacin versus tolterodine--a head-to-head study: finally! But not final?
    Staskin DR; Dmochowski RR; Wein AJ
    Curr Urol Rep; 2005 Nov; 6(6):403-4. PubMed ID: 16238911
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of tolterodine in children with dysfunctional voiding: an initial report.
    Munding M; Wessells H; Thornberry B; Riden D
    J Urol; 2001 Mar; 165(3):926-8. PubMed ID: 11176516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [More quality of life again with tolterodine].
    Praxis (Bern 1994); 2006 Oct; 95(42):1636. PubMed ID: 17111848
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder.
    Michel MC; de la Rosette JJ; Piro M; Schneider T
    Eur Urol; 2005 Jul; 48(1):110-5. PubMed ID: 15967259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Schaefer W
    J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
    [No Abstract]   [Full Text] [Related]  

  • 39. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity--a comment.
    Short DD
    Pharmacotherapy; 1999 Oct; 19(10):1188. PubMed ID: 10512072
    [No Abstract]   [Full Text] [Related]  

  • 40. Hallucinations with tolterodine.
    Williams SG; Staudenmeier J
    Psychiatr Serv; 2004 Nov; 55(11):1318-9. PubMed ID: 15534031
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.